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Summary
Background  and  purpose:  The  peak  of  restenosis  in  patients  implanted  with  bare  metal  stents
(BMS) is  thought  to  be  6  months  after  BMS  implantation,  but  the  development  of  restenosis  with
respect to  time  and  the  peak  of  restenosis  in  patients  implanted  with  drug-eluting  stents  (DES)
is not  known.  This  study  aims  to  reveal  the  rate  of  development  of  restenosis  with  respect  to
time in  patients  implanted  with  DES.
Methods:  A  total  of  282  patients  who  underwent  sirolimus-eluting  stent  (SES)  implantation  in
native coronary  arteries  at  our  hospital  were  evaluated  by  serial  quantitative  angiography  at  3
and 6  months,  and  based  on  the  latter  results,  at  1  and  2  years  after  SES  implantation.  Clinical
data were  collected  for  up  to  3  years.
Results:  Three-year  follow-up  data  were  obtained  for  261  patients.  The  3-year  incidence  of
clinically  driven  target-lesion  revascularization  (TLR)  was  6.1%  (16/261);  of  the  16  cases,  5
occurred at  3-month  follow-up,  7  at  6-month  angiographic  follow-up,  and  1  at  1-year  fol-
low up,  respectively.  While  minimum  lumen  diameter  (MLD)  of  these  vessels  that  underwent
TLR at  6  months  decreased  rapidly  after  the  3-month  angiographic  follow-up,  MLD  of  the  ves-
sels with  50—70%  stenosis  at  6-month  angiographic  follow-up  was  almost  unchanged  at  1-year
angiographic  follow-up;  however,  3  lesions  required  late  (i.e.  beyond  1  year)  revascularization.
Conclusions:  It  is  difﬁcult  to  predict  SES  restenosis  by  angiography.  SES  restenosis  begins
suddenly, shows  short-term  progression,  and  stops  suddenly.  However,  treatment  of  de  novo
coronary  stenosis  with  SES  is  asso
of TLR.
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Introduction
Percutaneous  coronary  intervention  (PCI)  is  a  major  treat-
ment  modality  for  patients  with  ischemic  heart  disease,  and
coronary  stent  implantation  is  widely  performed.  However,
restenosis  after  stent  implantation  is  one  of  the  major  lim-
itations  of  PCI.  Compared  to  bare  metal  stents  (BMS),  the
recently  introduced  drug-eluting  stents  (DES)  have  lesser
incidence  of  restenosis.  On  the  basis  of  the  results  of
randomized  trials,  DES  have  been  enthusiastically  adopted
by  interventional  cardiologists  [1,2], and  recent  long-term
follow-up  data  have  conﬁrmed  that  DES  implantation  pro-
vides  sustained  beneﬁt  for  up  to  5  years  [3].  Although  DES
have  signiﬁcantly  decreased  the  incidence  of  restenosis  and
the  need  for  revascularization,  restenosis  still  occurs  [3].
The  development  of  restenosis  is  considered  to  peak  at  6
months  after  BMS  implantation  [4],  however,  recent  stud-
ies  have  suggested  that  late  restenosis  occurs  after  DES
implantation,  and  reports  of  late-occurring  (i.e.  beyond  one
year)  symptomatic  restenosis  raise  questions  on  the  appro-
priate  timing  for  clinically  useful  angiographic  assessment
of  potential  restenosis.  In  fact,  the  temporal  pattern  of
restenosis  development  and  evolution  to  clinical  manifesta-
tion  requiring  revascularization  in  patients  implanted  with
DES  has  not  been  clearly  deﬁned.  This  study  aims  to  reveal
the  rate  of  development  of  restenosis  with  respect  to  time
in  patients  implanted  with  DES.
Materials and methods
Study  patients
Consecutive  patients  who  were  referred  to  our  center
between  June  1,  2004,  and  May  31,  2006,  and  under-
went  elective  PCI  using  sirolimus-eluting  stents  (SES)  were
selected.  Inclusion  criteria  were  as  follows:  >75%  stenosis
of  at  least  1  major  epicardial  coronary  artery  with  objec-
tive  evidence  of  myocardial  ischemia  or  >90%  stenosis  of  at
least  1  coronary  artery  with  typical  angina  without  provoca-
tive  testing.  A  total  of  282  patients  (age  >18  years)  were
enrolled  and  SES  were  implanted  in  361  native  coronary
arteries.  SES  were  implanted  for  de  novo  lesions  of  the
native  coronary  arteries.  All  patients  received  optimal  med-
ical  therapy,  including  anti-platelet  therapy,  anti-ischemic
therapy,  anti-hypertensive  therapy,  glycemic  control,  and
low-density  lipoprotein  (LDL)  cholesterol-lowering  therapy
with  statins.  The  target  for  LDL  therapy  was  to  reduce  the
LDL  to  <100  mg/dl.  All  patients  provided  informed  consent
for  the  procedure  and  follow-up  treatment,  and  the  protocol
was  approved  by  an  institutional  review  board.
Stent  placement  and  anticoagulant  therapy
Stent  implantation  techniques  have  been  described  in  detail
elsewhere  [1].  All  stents  were  implanted  using  a  commer-
cially  available  stent  delivery  system  (Cordis/Johnson  &
Johnson,  Bridgewater,  NJ,  USA).  Procedural  success  was
deﬁned  as  the  successful  deployment  of  the  stent  result-
ing  in  <25%  stenosis,  as  measured  by  quantitative  coronary
angiography.  Procedural  anticoagulation  and  anti-platelet
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herapies  were  administered  according  to  standard  proto-
ols  [5].
ngiographic  follow-up
ollow-up  angiography  was  performed  at  3  months,  6
onths,  1  year,  and  2  years  after  PCI.  The  3-  and  6-month
ngiographic  follow-up  examinations  were  performed  for
ll  patients.  The  1-year  angiographic  follow-up  examination
as  performed  for  only  the  patients  with  50—75%  stenosis
t  6-month  angiographic  follow-up.  The  2-year  angio-
raphic  follow-up  examination  was  performed,  if  possible
or  patients  who  had  <50%  stenosis  at  6-month  angiographic
ollow-up.  If  the  patients  developed  signs  of  ischemia,
ollow-up  angiography  was  performed  immediately.  All  cases
ith  angiographic  evidence  of  stent  thrombosis  were  not
onsidered  as  restenosis.  The  cases  of  restenosis  were
ivided  into  3  restenosis  groups  of  early  (<6  months),  gen-
ral  (6  months  to  1  year),  and  late  (>1  year)  phase.  Late
estenosis  was  diagnosed  on  the  basis  of  angiographic  evi-
ence  of  stenosis  of  a  widely  patent  stented  segment  at
-month  angiographic  follow-up  [6].
Quantitative  angiographic  analysis  was  performed  using
he  commercially  available  CAAS  II  5.4  (Pie  Medical  Imag-
ng,  Maastricht,  the  Netherlands).  Quantitative  angiographic
nalysis  of  the  control  and  follow-up  angiograms  was
erformed  using  nearly  identical  views;  an  intracoronary
njection  of  3  mg  of  nitrate  was  administered  before  angiog-
aphy.  Minimal  lumen  diameter  (MLD)  and  reference  vessel
iameter  were  measured  immediately  after  PCI,  at  the  rou-
ine  follow-up  examinations,  and  at  the  time  of  detection
f  restenosis.
linical  follow-up
linical  follow-up  data  were  obtained  by  either  a  review  of
he  hospital  records  or  telephone  interview  of  the  patients
r  their  referring  physicians.  The  major  clinical  events  stud-
ed  were  death,  myocardial  infarction  (MI),  thrombosis,
arget-lesion  revascularization  (TLR),  target-vessel  revascu-
arization  (TVR),  and  coronary  angioplasty  of  a  non-stented
essels  (new  lesion).  Death  was  deﬁned  to  include  death
rom  any  cause.  MI  was  deﬁned  as  an  increase  in  serum  cre-
tine  kinase  level  to  more  than  twice  the  normal  value,  in
ssociation  with  new  pathological  Q  waves.  Stent  thrombosis
as  deﬁned  as  any  of  the  following  events  after  the  proce-
ure:  angiographic  documentation  of  stent  occlusion  with  or
ithout  the  presence  of  thrombus  associated  with  an  acute
schemic  event,  unexpected  sudden  death,  or  MI  that  was
ot  clearly  attributable  to  another  coronary  lesion  [7].
LR  and  TVR
LR  was  deﬁned  as  an  intervention  repeated  to  control  lumi-
al  stenosis  within  the  stent  or  in  the  5-mm  proximal  or
istal  segments  adjacent  to  the  stent.  TLR  was  performed  if
ollow-up  angiography  showed  a  stenosis  of  >75%  of  the  ves-
el  diameter  with  or  without  ischemic  symptoms.  TVR  was
eﬁned  as  a  clinically  driven  PCI  or  bypass  of  the  stented
esion  or  any  segment  of  the  epicardial  coronary  artery
28  K.  Tanaga  et  al.
Table  1  Baseline  characteristics  of  the  patients  and
lesions.
Characteristic  Value
Patients
No.  282
Mean  (±SD)  age—–yr  67.1  ±  9.6
Sex—–M/F  223/59
Diabetes  mellitus—–no.  101
Hypertension 153
Hyperlipidemia 151
Old myocardial  infarction 27
Post  PCI 12
Post  CABG 11
Post  cerebrovascular  disease  7
Lesions
No. 361
Artery  affected  —–no.
Left  anterior  descending  coronary  170
Circumﬂex  coronary  79
Right  coronary  112
ACC/AHA  lesion  classiﬁcation
A 21
B1 88
B2 144
C 108
Lesion  length  (mm) 26.1  ±  11.2
Stent  diameter  (mm) 2.87  ±  0.37
Stents  per  lesion  1.25  ±  0.48
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Table  2  Clinical  events  studied  during  3-year  follow-up.
Death  9
Myocardial  infarction  7
Thrombosis  Deﬁnite:  4,  probable:  1
TLR 16
TVR 21
New lesion  23
TLR, target lesion revascularization; TVR, target vessel.
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Quantitative  coronary  angiographic  analysis
All  261  patients  underwent  the  3-  and  6-month  angiographic
follow-up.  17  patients  underwent  the  1-year  angiographic
Table  3  Predictors  of  target  lesion  revascularization  by
Cox regression  analysis.
Variable  Odds  ratio  95%  CI  p  Value
Diabetes  mellitus 1.16  0.7—1.92  0.537
Hypertension  1.04  0.64—1.74  0.867
Hyperlipidemia  0.83  0.49—1.35  0.442PCI, percutaneous coronary intervention; CABG, coronary artery.
ontaining  the  stented  lesion.  New  lesion  was  deﬁned  as
 clinically  driven  PCI  or  bypass  of  the  epicardial  coronary
rtery  without  stented  lesion.
tatistical  analysis
ata  are  summarized  as  mean  ±  SD.  The  Student  t-test
as  used  when  means  were  compared.  A  multivariate  Cox
egression  was  used  to  assess  independent  predictors  of  TLR.
-values  of  <0.05  were  considered  statistically  signiﬁcant.
ll  statistical  analyses  were  performed  using  SAS  software
JMP  version  5.1,  Cary,  NC,  USA).
esults
n-hospital  outcome
he  baseline  clinical  characteristics  of  the  patients  and  the
oronary  lesions  are  shown  in  Table  1.  During  this  study,
61  lesions  were  treated  in  282  patients.  All  stents  were
uccessfully  implanted  in  all  the  patients.
linical  follow-uplinical  outcomes  at  the  3-year  follow-up  are  shown  in
able  2.  The  3-year  follow-up  data  of  261  out  of  282  patients
92.2%)  were  obtained.  Nine  patients  died  during  the  studyigure  1  Time  to  documentation  of  restenosis  in  months.
eriod.  MI  occurred  in  7  patients  and  stent  thrombosis
ccurred  in  5,  of  which  only  1  patient  had  discontinued  the
nti-platelet  therapy.  The  incidence  of  clinically  driven  TLR
ithin  3  years  after  SES  implantation  was  6.1%  (16/261).  Of
he  16  cases  of  clinically  driven  TLR,  5  occurred  at  early
hase,  8  at  general  phase,  and  3  at  late  phase,  respectively
Fig.  1).  The  incidence  of  clinically  driven  TVR  within  3  years
fter  SES  implantation  was  8.0%  (21/261).  Twenty-three
esions  of  the  epicardial  coronary  arteries  without  stented
esions  (new  lesion)  were  treated  with  PCI  or  bypass  during
he  3  years.  All  the  261  patients  received  optimal  medical
herapy  during  the  3  years  follow-up  except  those  who  were
ntolerant  to  the  administered  drugs.  Of  the  213  patients
reated  with  statins,  132  achieved  the  target  LDL  level.  The
ultivariate  analyses  identiﬁed  the  following  predictors  of
LR:  stent  diameter  (odds  ratio  [OR]  1.99,  p  =  0.009),  lesion
ength  (OR:  1.79,  p  =  0.02),  and  numbers  of  stents  implanted
OR:  1.63,  p  =  0.06)  (Table  3).Lesion length  (>30  mm)  1.79  1.08—2.95  0.02
Stent diameter  (<2.5  mm)  1.99  1.18—3.77  0.009
Stents per  lesion  (>1)  1.63  0.97—2.67  0.06
Restenosis  after  implantation  of  sirolimus-eluting  stent  29
Figure  2  Serial  changes  in  the  mean  minimal  lumen  diameter
Figure  4  Serial  changes  in  the  mean  minimal  lumen  diame-
ter (MLD)  in  the  7  lesions  of  7  patients  who  underwent  target
lesion revascularization  at  6  months  after  sirolimus-eluting
stent implantation.  MLD  ()  compared  with  a  reference  diam-
eter ().  Numbers  shown  are  mean  ±  SD.
Figure  5  Serial  changes  in  the  mean  minimal  lumen  diameter
(
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t(MLD)  in  the  48  lesions  of  34  patients  who  underwent  2-year
angiographic  follow-up.  MLD  ()  compared  with  a  reference
diameter  (©).  Numbers  shown  are  mean  ±  SD.
follow-up  according  to  study  protocol.  34  patients  under-
went  the  2-year  angiographic  follow-up.  Fig.  2  shows  MLD
and  reference  diameter  of  the  48  lesions  of  34  patients  that
were  angiographically  examined  at  2-year  follow-up.  MLD  of
the  48  lesions  at  2-year  angiographic  follow-up  was  almost
unchanged  after  SES  implantation  (from  2.326  ±  0.338  mm
to  2.142  ±  0.227  mm,  p  =  0.42).  Fig.  3  shows  MLD  and  refer-
ence  diameter  of  the  5  lesions  that  were  treated  with  TLR
at  3  months.  MLD  rapidly  decreased  during  the  period  from
immediately  after  SES  implantation  to  3  months  later  (from
1.722  ±  0.136  mm  to  0.748  ±  0.205  mm,  p  <  0.005).  Fig.  4
shows  MLD  and  reference  diameter  of  the  7  lesions  that  were
treated  with  TLR  at  6  months.  MLD  decreased  rapidly  during
the  period  from  3  months  after  implantation  to  6  months
later  (from  2.028  ±  0.159  mm  to  0.801  ±  0.1  mm,  p  <  0.005).
17  lesions  showed  50—75%  stenosis  at  the  6-month  angio-
graphic  follow-up,  and  all  17  patients  were  followed  up
angiographically  at  1  year;  Fig.  5  shows  MLD  and  refer-
ence  diameter  of  these  17  lesions.  TLR  was  performed  for
only  1  lesion  that  showed  progressive  stenosis  at  the  1-
year  angiographic  follow-up.  However,  MLD  of  the  vessels
with  50—75%  stenosis  at  6-month  angiographic  follow-up
was  almost  unchanged  at  1-year  angiographic  follow-up
(from  1.452  ±  0.154  mm  to  1.4  ±  0.209  mm,  p  =  0.51).  Three
patients  with  <50%  stenosis  at  the  6-month  angiographic
Figure  3  Serial  changes  in  the  mean  minimal  lumen  diame-
ter (MLD)  in  the  5  lesions  of  5  patients  who  underwent  target
lesion revascularization  at  3  months  after  sirolimus-eluting
stent implantation.  MLD  ()  compared  with  a  reference  diam-
eter  (©).  Numbers  shown  are  mean  ±  SD.
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sMLD)  in  the  17  lesions  of  17  patients  who  underwent  1-year
ngiographic  follow-up.  MLD  ()  compared  with  a  reference
iameter  (©).  Numbers  shown  are  mean  ±  SD.
ollow-up  developed  ischemic  symptoms,  and  underwent
LR.  Of  these,  1  patient  underwent  TLR  13  months  after  1
ES  was  implanted  (2.5  ×  18  mm)  and  suffered  from  hyper-
ension,  1  patient  underwent  TLR  28  months  after  2  SES
ere  implanted  (2.5  ×  23  mm  and  2.5  ×  28  mm)  and  suf-
ered  from  diabetes  mellitus  and  hypertension,  and  the  last
atient  underwent  TLR  33  months  after  1  SES  was  implanted
3.0  ×  23  mm)  and  suffered  from  hypertension  and  hyperlipi-
emia.  The  patient  who  underwent  TLR  at  28  months  after
ES  implantation  underwent  the  2-year  angiographic  follow-
p;  Fig.  6  shows  MLD  and  reference  diameter  of  this  lesion
igure  6  Serial  changes  in  the  mean  minimal  lumen  diameter
MLD)  in  the  patient  who  underwent  target  lesion  revascular-
zation  at  28  months  after  sirolimus-eluting  stent  implantation.
LD  ()  compared  with  a  reference  diameter  (©).  Numbers
hown  are  mean  ±  SD.
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hat  was  treated  with  TLR  at  28  months  after  SES  implanta-
ion.  MLD  decreased  rapidly  within  4  months  after  the  2-year
ngiographic  follow-up  (from  1.96  mm  to  0.74  mm).
iscussion
n  this  study,  we  conﬁrmed  that  SES  is  associated  with  a
avorable  clinical  outcome.  The  safety  and  the  efﬁcacy
f  SES  persisted  for  3  years.  During  these  3  years,  TLR
as  required  in  only  6.1%  of  the  patients.  These  favor-
ble  data  encourage  the  use  of  SES.  In  81%  of  the  patients,
estenosis  occurred  in  the  early  and  general  phases  but
estenosis  occurred  in  the  late  phase  for  19%  of  the  patients
3  patients).  All  the  16  patients  who  underwent  TLR  received
ptimal  medical  therapy  during  the  3  years  of  follow-up  and
here  was  no  signiﬁcant  difference  between  late  resteno-
is  and  others.  It  is  difﬁcult  to  predict  the  occurrence  of
ate  restenosis  in  the  patients  implanted  with  SES.  Six-
een  patients  with  restenosis  were  treated  by  3  approaches,
ncluding  SES  (56%  patients),  paclitaxel-eluting  stent  (PES)
18.8%  patients),  and  balloon  angioplasty  (25%  patients).  Of
he  16  patients  who  underwent  TLR,  2  patients  who  were
reated  with  SES,  1  patient  who  was  treated  with  PES,  and  2
atients  who  were  treated  with  balloon  angioplasty  under-
ent  re-TLR  by  SES.  After  re-TLR  by  SES,  there  was  no
atient  who  developed  new-onset  symptoms  and  required
urther  TLR.  Re-stenting  with  DES  was  protective  [8].
MLD  at  2  years  follow-up  was  almost  identical  to  that
fter  the  procedure  in  most  of  the  patients  who  underwent
-year  angiographic  follow-up.  However,  mean  MLD  slightly
ecreased  during  the  period  from  after  the  procedure  to
 years  after  and  improvement  in  MLD  was  not  observed.
rom  the  2-year  serial  quantitative  angiographic  data,  we
ere  unable  to  determine  the  time  when  the  progression  of
estenosis  stops.
Mean  MLD  of  the  patients  who  underwent  TLR  at  3  months
as  very  small.  Therefore,  the  cause  of  restenosis  at  3
onths  could  be  the  underexpansion  of  SES.  Careful  mon-
toring  may  be  required  to  detect  very  early  restenosis  in
atients  with  stent  underexpansion.
Clinically  driven  TLR  was  performed  in  patients  who
howed  a  widely  patent  stented  segment  at  the  6-month
ngiographic  follow-up.  This  ﬁnding  suggests  that  increase
f  neointimal  tissue  volume  started  from  6  months  after
ES  implantation  in  1.1%  of  patients.  Furthermore,  patients
ho  underwent  TLR  at  28  months  showed  a  widely  patent,
tented  segment  at  2-year  follow-up.  This  ﬁnding  suggests
hat  the  volume  of  neointimal  tissue  rapidly  increased  within
nly  4  months  after  2  years.  Thus,  SES  restenosis  begins
uddenly  and  shows  short-term  progression.
Restenosis  is  the  healing  response  of  the  arterial  wall  to
echanical  injury  [9].  The  SES  implantation  site  shows  a
igniﬁcant  delay  in  arterial  healing  and  poor  endothelializa-
ion,  as  compared  to  the  sites  of  BMS  implantation  [10,11].
utopsy  of  patients  implanted  with  SES  for  16  months,
evealed  nearly  complete  neointimal  healing  at  16  months
12].  However,  the  stent  surface  may  not  completely  heal  in
ll  the  patients  implanted  with  SES.  The  apposition  of  the
tent  strut  to  the  arterial  wall  is  not  completely  uniform  and
his  inﬂuences  drug  delivery.  Within  the  same  stent,  some
truts  may  remain  bare,  whereas  others  may  show  healingK.  Tanaga  et  al.
y neointimal  growth.  Because  of  poor  endothelialization,
rterial  healing  may  be  abruptly  triggered  by  some  factors
nd  may  begin  suddenly.
Inﬂammatory  cell  inﬁltration  is  identiﬁed  as  a  mile-
tone  in  the  temporal  sequence  of  restenosis  [13]. In
ontrast  to  BMS,  SES  provoke  eosinophilic/heterophilic  inﬁl-
ration  of  the  arterial  walls  [10]. SES  are  coated  with  a
urable  polymeric  coating  which  may  induce  an  inﬂam-
atory  response  and  this  response  may  cause  short-term
rogression  of  restenosis.  Coronary  angioscopic  observations
evealed  yellow  neointima  at  the  SES  implanted  site  [14].
he  constitution  of  the  neointima  at  the  SES  implanted  site
ay  differ  from  the  neointima  at  the  BMS  implanted  site.
The  mean  MLD  of  the  patients  who  showed  50—75%
tenosis  at  the  6-month  angiographic  follow-up  was  almost
nchanged  at  the  1-year  angiographic  follow-up.  This  ﬁnding
uggests  that  the  volume  of  the  neointimal  tissue  stopped
ncreasing  at  6  months.  In  this  study,  75%  of  the  TLR  were
erformed  within  6  months,  but  in  the  RABEL  study,  TLR
ere  performed  after  6  months  [3].  Performance  of  angio-
raphic  follow-up  increased  the  incidence  of  TLR  among
atients  implanted  with  PES  [15]. The  patients  who  under-
ent  TLR  at  the  angiographic  follow-up  did  not  develop
schemic  symptoms.  Progression  of  SES  restenosis  may  stop
nd  TLR  may  not  be  necessary  until  the  appearance  of
schemic  signs.
In  conclusion,  it  is  difﬁcult  to  predict  SES  restenosis  by
ngiography.  SES  restenosis  begins  suddenly,  shows  short-
erm  progression,  and  stops  suddenly.  However,  treatment
f  de  novo  coronary  stenosis  with  SES  is  associated  with  a
ustained  clinical  beneﬁt  and  very  low  incidence  of  TLR.  In
his  study,  there  was  more  PCI  required  for  a  new  lesion
han  TVR.  Patients  implanted  with  SES  should  be  carefully
onitored  for  signs  of  ischemia,  and  their  life  style  and
ardiovascular  risk  should  be  assessed.
tudy  limitations
his  study  has  several  limitations.  Firstly,  1-year  and  2-year
ngiographic  follow-up  examinations  were  not  performed
or  all  patients  implanted  with  SES.  Secondly,  this  study
nalyzed  patients  from  a  single  center.  Thirdly,  although  a
ell-validated  system  of  quantitative  coronary  angiography
as  used,  the  analysis  was  not  performed  in  a  core  labora-
ory.
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